Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease drug that the company developed with Japanese partner Eisai — reversing an earlier decision not to approve the drug.
The number of Americans who applied for unemployment benefits in the week before the Thanksgiving holiday dipped to a seven-month low in a sign of strength for a steadily expanding U.S. economy.